May 08, 2013 (M2 PRESSWIRE via COMTEX) --
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, May 9th 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. MediciNova Inc (NASDAQ:MNOV), Amicus Therapeutics Inc (NASDAQ:FOLD), Kratos Defense and Security Solutions Inc (NASDAQ:KTOS), Acorn Energy Inc (NASDAQ:ACFN), Inuvo Inc (AMEX:INUV), Omeros Corp (NASDAQ:OMER) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Thursday:
Symbol Company # of Reports Quarter Release Time
MNOV MediciNova Inc 12 Quarter Q1 After
FOLD Amicus Therapeutics Inc 6 Quarter Q1 After
KTOS Kratos Defense and Security Solutions Inc 12 Quarter Q1 After
ACFN Acorn Energy Inc 12 Quarter Q1 After
INUV Inuvo Inc 12 Quarter Q1 After
OMER Omeros Corp 12 Quarter Q1 After
This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.
MediciNova Inc (NASDAQ:MNOV) - MediciNova, Inc., a development stage biopharmaceutical company, focuses on the acquisition and development of small-molecule therapeutics for the treatment of serious diseases for the United States market. Its product pipeline consists of six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorder, preterm labor, and urinary incontinence, as well as two preclinical stage compounds for the treatment of thrombotic disorders. The company s primary product candidates include MN-221 for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations; and MN-166, which is in Phase Ib/II trials for neurological disorders. MediciNova, Inc. was founded in 2000 and is headquartered in San Diego, California..
Amicus Therapeutics Inc (NASDAQ:FOLD) - Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of lysosomal storage disorders and diseases of neurodegeneration. Its drugs are known as pharmacological chaperones, which selectively bind to the target protein, enhance the stability of the protein, help it fold into the three-dimensional shape, as well as allow proper trafficking of the protein, thereby increasing protein activity, enhance cellular function, and reduce cell stress. The company focuses on the development of pharmacological chaperone monotherapy programs and pharmacological chaperones in combination with enzyme replacement therapy (ERT). Its pharmacological chaperone monotherapy programs for genetic diseases include migalastat HCl, which is in Phase III clinical trial for the treatment of Fabry disease; and AT3375, which is in preclinical stage for the treatment of Parkinson s disease. The company s pharmacological chaperone-ERT combination programs comprise Migalastat HCl co-administered with ERT for patients with Fabry disease receiving ERT treatment with any genetic mutation; AT2220 (duvoglustat HCl) co-administered with ERT for Pompe disease; AT3375 and afegostat tartrate co-administered with ERT for Gaucher disease; and pharmacological chaperone programs for other lysosomal storage diseases. Amicus Therapeutics, Inc. has a license and collaboration agreement with Glaxo Group Limited to develop and commercialize migalastat HCl. The company was founded in 2002 and is based in Cranbury, New Jersey..
Kratos Defense and Security Solutions Inc (NASDAQ:KTOS) - Kratos Defense & Security Solutions, Inc. provides mission critical products, services, and solutions in the United States. The company s Kratos Government Solutions segment offers various services comprising weapon systems sustainment, lifecycle support, and extension; command, control, communications, computing, combat systems, intelligence, surveillance, and reconnaissance services, including cybersecurity, cyberwarfare, information assurance, and situational awareness solutions; military range operations and technical services; missile, rocket, and weapons systems test and evaluation; mission launch services; modeling and simulation; unmanned aerial vehicle products and technology; advanced network engineering and information technology services; and public safety, security, and surveillance systems integration. Its Public Safety & Security segment provides independent integrated solutions for homeland security, public safety, critical information, and security and surveillance systems. This segment s solutions consists of designing, installing, and servicing building technologies that protect people, critical infrastructure, assets, information, and property in various areas, such as the design, engineering, and operation of command and control centers; design, engineering, deployment, and integration of access control; building automation and control; communications; digital and closed circuit television security and surveillance; fire and life safety; maintenance services; and product support services. The company primarily serves the United States government agencies, including the department of defense, classified agencies, intelligence agencies, other national security agencies, and homeland security related agencies. The company was formerly known as Wireless Facilities, Inc. and changed its name to Kratos Defense & Security Solutions, Inc. in September 2007. The company was founded in 1994 and is headquartered in San Diego, California..
Acorn Energy Inc (NASDAQ:ACFN) - Acorn Energy, Inc., through its subsidiaries, provides technology driven solutions for energy infrastructure asset management worldwide. It offers sonar and acoustic related solutions for energy, defense, and commercial markets with a focus on underwater site security for strategic energy installations and other acoustic systems, as well as develops and produces real-time embedded hardware and software. The company also develops and markets remote monitoring systems to electric utilities and industrial facilities, which are used in a range of utility applications, including outage management, power quality monitoring, system planning, trouble shooting and proactive maintenance, and condition monitoring; and provides the intelligence to transmission and distribution network operators. In addition, it develops and produces fiber optic sensing systems for the energy, commercial security, and defense markets. The company s patented ultra-high sensitivity fiber optic sensors are designed to replace electronic sensors with fiber optic sensors. Further, it engages in the design, manufacture, marketing, and sale of wireless remote systems that monitor standby power generation, backup power generators, remote powered equipment, cellular towers, emergency towered communications, and remote tower sites; cathodic protection products to monitor pipeline integrity; and other wireless remote systems. Acorn Energy, Inc. was founded in 1986 and is based in Montchanin, Delaware..
Inuvo Inc (AMEX:INUV) - Inuvo, Inc. provides software and analytics technology solutions through the Internet for use by online advertisers and Website publishers. The company operates in two segments, Performance Marketing, and Web Properties. The Performance Marketing segment designs, builds, implements, manages, and sells various technology platforms. Its solutions include ValidClick service at validclick.com, which is a fraud filtering pay-per-click marketplace where publishers integrate advertisements within their Websites based on the demographics and natural search behaviors of the consumer; MyAP affiliate platform at myap.com, an affiliate tracking and management software solution that provide advertisers the ability to sign up, manage, and track the activities of their publishers; and LocalXML service at localxml.com, which allows publishers to make real-time calls to the LocalXML database. The Web Properties segment designs, builds, and implements offers and/or Websites that enable sale of products, services, data, and advertising. It operates Yellowise.com directory search Website, a local search and review Website powered by the LocalXML service for users to search by category and location, and receive requested search results; and BargainMatch consumer product comparison-shopping and CashBack website at BargainMatch.com, which allows publishers to offer their visitors an online shopping experience with rewards to consumers; and Kowabunga consumer daily deals website at kowabunga.com for households and retail advertisers of rural America. The company was formerly known as Kowabunga Inc. and changed its name to Inuvo, Inc. in July 2009. Inuvo, Inc. is headquartered in New York, New York..
Omeros Corp (NASDAQ:OMER) - Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. It derives product candidates from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company s product candidates comprise OMS302, which is in Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program evaluating the product candidate s safety and ability to improve postoperative joint function and reduce pain following arthroscopic partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. It also engages in developing proprietary compositions that comprise peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse. The company s pipeline of preclinical product development programs includes PDE10 for schizophrenia/cognitive disorders; PDE7 for addictions and compulsive disorders, and movement disorders; MASP2 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; and Plasmin for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington..
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Thomas Ronk, CEO
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to firstname.lastname@example.org.